Key clinical point: Physicians should consider prescribing neurology drugs with lower out-of-pocket costs to improve patient adherence.
Major finding: A $50 increase in drug price to patient resulted in an 12% decrease in adherence for patients taking cholinesterase inhibitors for dementia, and an 8% decrease among those taking gabapentinoid drugs for neuropathy.
Study details: A retrospective cohort study of diagnostic and prescription records for more than 80,000 patients from a large commercial insurer.
Disclosures: The American Academy of Neurology sponsored the study. The lead author and two coauthors reported industry funding.
Reynolds EL et al. Neurology. 2020 Feb 19. doi: 10.1212/WNL.0000000000009039.